Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board of Directors
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as Cellvation’s Executive Chairman, Dr. Rosenwald is Chairman and CEO of Fortress Biotech, Cellvation’s parent company, and a member of Fortress’ Board of Directors. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm that is affiliated with Fortress. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.
Frank Taffy, J.D.
Co-Founder, President, Chief Executive Officer and Director
Mr. Taffy was appointed President, Chief Executive Officer and Director of Cellvation, Inc. in October 2016; he also currently serves as President, Chief Executive Officer, and member of the Board of Directors of Helocyte, Inc., a company he also co‐founded that is focused on the development of novel immunotherapies for cancer and infectious disease. Mr. Taffy identified the programs that formed the basis of Cellvation (and Helocyte) during his role as Entrepreneur in Residence at Fortress Biotech. Prior to Fortress, Mr. Taffy held the positions of Head (Senior Director) of Business Affairs at Forest Labs (now Allergan Plc) and Director of Corporate Development at Life Technologies (now Thermo Fisher Scientific), where he also held Board positions on behalf of the company. Mr. Taffy started his career as Counsel for Intellectual Property at The Procter and Gamble Company. He holds a B.A. in biochemistry from the University of North Texas and a J.D. from Syracuse University College of Law.
Elizabeth Clark Moore, M.S.
Executive Vice President of Regulatory Affairs
Ms. Moore has served as our Executive Vice President of Regulatory Affairs since May 2015. She has over thirty years of experience in strategic regulatory registration and product development; management of FDA and global health authority interactions; and completion of regulatory and other due diligence for acquisition targets. Ms. Moore started her career at the National Institutes of Health (“NIH”), having served eight years with posts at both the National Institute of Allergy and Infectious Diseases and the National Cancer Institute. Her industry experience spans traditional pharmaceutical companies as well as biotech start-ups. Following her tenure at the NIH, Ms. Moore joined Agouron Pharmaceuticals as Director, Regulatory Affairs for Oncology Development. Subsequent to the Pfizer-Warner Lambert acquisition of Agouron, Ms. Moore was appointed Regulatory Affairs Site Head (Senior Director) of Pfizer Global R&D in La Jolla, CA. For the past fifteen years, Ms. Moore has directed global regulatory affairs strategy and operations for both public and private companies, holding senior-level positions at Coronado Biosciences (now Fortress), Paramount BioSciences, Tracon Pharmaceuticals, Salmedix (acquired by Cephalon), and most recently, Fate Therapeutics. Ms. Moore received her B.S. in Pharmacy from the University of Georgia and M.S. in Administrative Science from the Johns Hopkins University.